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CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Prevention of Epstein-Barr virus–lymphoproliferative disease by molecular
monitoring and preemptive rituximab in high-risk patients after allogeneic
stem cell transplantation
Joost W. J. van Esser, Hubert G. M. Niesters, Bronno van der Holt, Ellen Meijer, Albert D. M. E. Osterhaus,
Jan Willem Gratama, Leo F. Verdonck, Bob Lo¨wenberg, and Jan J. Cornelissen
Recipients of a partially T-cell–depleted
(TCD) allogeneic stem cell transplantation
(allo-SCT) developing reactivation of Ep-
stein-Barr virus (EBV) with quantified viral
DNA levels exceeding 1000 genome equiva-
lents/milliliter (geq/mL) are at high risk for
EBV–lymphoproliferative disease (EBV-
LPD). We studied whether preemptive
therapy with rituximab prevents EBV-LPD,
LPD-mortality, and abrogates viral reactiva-
tion in high-risk patients. We monitored 49
recipients of a TCD allo-SCT weekly for EBV
reactivation by quantitative real-time poly-
merase chain reaction (PCR). Preemptive
therapy by a single infusion of rituximab
was given to patients with viral reactivation
more than or equal to 1000 geq/mL. Results
were compared with an historical control
group of patients retrospectively monitored
for EBV reactivation at similar intervals.
There were 17 prospectively monitored pa-
tients who showed EBV reactivation more
than or equal to 1000 geq/mL and 15 re-
ceived preemptive therapy. Median time to
preemptive therapy was 113 days (range,
41-202 days) after SCT. There were 14 pa-
tients who showed complete response (CR)
as characterized by prevention of EBV-LPD
and complete clearance of EBV-DNA from
plasma, which was achieved after a median
number of 8 days (range, 1-46 days). One
patient progressed to EBV-LPD despite pre-
emptive therapy, but obtained CR after 2
infusions of rituximab and donor lympho-
cyte infusion. There were 2 patients who
had already developed EBV-LPD prior to
preemptive rituximab, but obtained CR fol-
lowing 2 rituximab infusions. Comparison
of this prospectively followed series to our
historical cohort with the same high-risk
profile showed a reduction of EBV-LPD inci-
dence (18% 9% versus 49% 11%, re-
spectively) and a complete abrogation of
LPD-mortality (0% versus 26% 10%, re-
spectively) (P .04) at 6 months from EBV-
DNA more than or equal to 1000 geq/mL.
Frequent quantitative monitoring of EBV
reactivation and preemptive therapy by ritux-
imab improves outcome in patients at high
risk of EBV-LPD. (Blood. 2002;99:4364-4369)
© 2002 by The American Society of Hematology
Introduction
Herpes viruses including cytomegalovirus (CMV) and Epstein-Barr
virus (EBV) continue to affect outcome of allogeneic hematopoietic
stem cell transplantation (allo-SCT) and solid organ transplantation.
Considerable progress has been made in the last decade in the ability to
prevent CMV infection and CMV disease.1 Key elements to that effect
are the accurate identification of high-risk patients and the introduction
of new effective antiviral agents.2 Currently, a risk-adapted strategy with
preemptive or prophylactic ganciclovir in patients with a high-risk
profile for CMV disease has become the preferred approach. 3
In contrast to CMV, the precise identification of patients at high risk
for EBV–lymphoproliferative disease (EBV-LPD) has been hampered
by lack of early and sensitive markers of EBV reactivation, which
accurately predict impending EBV-LPD. The use of polymerase chain
reaction (PCR)–based assays, however, has enabled the early diagnosis
of EBV-LPD and also the monitoring of EBV reactivation.4-10 We
recently showed a high incidence of EBV reactivation after allo-SCT.10
However, only recipients of a T-cell–depleted (TCD) allo-SCT appeared
to be at risk for EBV-LPD. Furthermore, impending EBV-LPD could
quantitatively be predicted by the frequent monitoring of viral load in
plasma by quantitative real-time PCR. A viral load of 1000 genome
equivalents per milliliter (geq/mL) proved to be a level of EBV
reactivation associated with a high predictive value. Clearly, the
prevention of EBV-LPD in high-risk patients would be preferable, as
outcome of established EBV-LPD is still not optimal.9-14
The recent introduction of rituximab has provided a relatively simple
and safe treatment modality,15,16 which has already been applied in
LPD-treatment,10,14,17,18 but might be preferred for prevention in a
selected group of high-risk patients. We set out to study whether the
preemptive use of rituximab in TCD allo-SCT patients with viral
reactivation of at least 1000 geq/mL would prevent the development of
EBV-LPD. By comparing results with an historical control group of
patients with a similar risk profile, it is shown that viral reactivation,
progression to EBV-LPD, and mortality from EBV-LPD can effectively
be abrogated by preemptive therapy selectively given to patients at high
risk of developing EBV-LPD.
Patients, materials, and methods
Prospective cohort
We prospectively monitored 49 consecutively treated patients receiving a
partial TCD allo-SCT either from an HLA antigen genotypically matched
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sibling donor (Sib; n 35) or a matched unrelated donor (MUD; n 14)
following myeloablation at weekly intervals for EBV-DNA between
January 1999 and March 2001 (Table 1). There were 21 patients who had
standard-risk underlying disease and 28 patients who suffered from
poor-risk disease. Standard risk was defined by acute lymphoblastic
leukemia (ALL) in first complete remission (CR1), acute myeloid leukemia
(AML) in CR1, chronic myeloid leukemia (CML) in first chronic phase
(CP1), and untreated (very) severe aplastic anemia (SAA). All other
diagnoses were considered poor risk. One donor/recipient pair had negative
EBV serology, 4 had discordant EBV serology, and the remaining
donor/recipient pairs had positive EBV serology (antiviral capsid antigen
IgG) prior to transplantation. Patients experiencing an EBV reactivation
more than or equal to 1000 geq/mL were admitted to receive preemptive
B-cell immunotherapy by use of a single infusion of rituximab (MabThera;
Roche, Basel, Switzerland). Prior to infusion, patients were carefully
examined for signs and symptoms of EBV-LPD. Patients with an estab-
lished diagnosis of EBV-LPD were eligible for a therapeutic protocol
including 2 infusions of rituximab followed by donor lymphocyte infusion
(DLI) if the viral load had not been reduced to less than 50% by 72 hours
after first rituximab infusion as previously described.9 Transplant and
rituximab protocols were approved by local institutional review boards and
all patients provided informed consent.
Historical cohort
We included 85 consecutively treated patients receiving a TCD allo-SCT as
controls. The retrospective monitoring of EBV load was performed at
weekly intervals in these patients; the results were reported recently.10
Patients were treated at Utrecht Medical Center and at Erasmus Medical
Center/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands, using
the same protocols for transplantation and graft manipulation. Records of
these 85 patients were updated for the present study.
EBV reactivation and EBV-LPD
The real-time PCR assay for detection of EBV-DNA in plasma has been
described before.8 In short, primers were selected from the EBV-DNA
genome encoding the BNRF1-p143 protein and results were related to a
reference standard quantified by electron microscopy. The assay accurately
detects viral DNA in plasma over a linear span between 50 and 107 geq/mL.
Reactivation was defined by a plasma EBV-DNA exceeding 50 geq/mL in
donor/recipient pairs with positive EBV serology prior to transplantation.
Viral load was prospectively monitored at weekly intervals starting at the
time of SCT until day 180 after SCT and beyond day 180 in patients with
chronic graft-versus-host disease (GVHD). A diagnosis of EBV-LPD was
made on lymph node histology and/or cytology as described recently,9,10
and was classified according to the criteria of Knowles et al.19
Transplantation
Most patients received cyclophosphamide (120 mg/kg) and total body
irradiation (TBI) (6 Gy on each of 2 successive days with partial shielding
of the lungs for a total lung dose of 2  4.5 Gy) as a conditioning regimen
(Table 1). Rabbit antithymocyte globulin (ATG) (Imtix Sangstat, Am-
stelveen, The Netherlands) was added (2 mg/kg from day 7 through day
3) for patients who received an unrelated donor graft for prevention of
rejection (Table 1). Hematopoietic stem cells were obtained by bone
marrow aspiration under general anesthesia or by peripheral blood stem cell
collection. Grafts were partially depleted of T cells using sheep erythrocyte
rosetting or CD34 selection (Miltenyi Biotech GmbH, Bergisch-Gladbach,
Germany). The T-cell number in the graft was adjusted to a fixed low
number of 105 CD3 T cells/kg, if the depletion procedure had resulted in
less than 105 CD3 T cells/kg (recipient body weight).20 Supportive care
protocols were as previously described.9,10
Preemptive therapy
Patients with an EBV reactivation more than or equal to 1000 geq/mL
within 180 days following allo-SCT were admitted to receive preemptive
rituximab. In order to verify for EBV-LPD at initiation of preemptive
therapy, physical examination, computerized tomography (CT), bone
marrow morphology, and flow cytometry were performed. Rituximab was
given as a single infusion (375 mg/m2 dissolved in 0.9% NaCl in a final
concentration of 1 mg/mL) and immunosuppressive medication was
continued. EBV load was monitored daily during the first 72 hours, then
twice weekly until 2 negative test results were obtained and thereafter at
each outpatient visit. Absolute B-cell numbers were evaluated prior to and
within 1 week and at 1, 3, 6, 9, and 12 months following rituximab infusion.
Complete response to preemptive rituximab was defined as clearance of
EBV-DNA ( 50 geq/mL) from plasma and absence of signs and symptoms
of EBV-LPD.
Endpoints and statistical analysis
Data were analyzed as of May 2001. Endpoints of the study included (1)
incidence of viral reactivation more than or equal to 1000 geq/mL, (2) the
incidence of EBV-LPD, (3) LPD mortality, (4) EBV load, and (5) B-cell
recovery following preemptive rituximab infusion. Patient characteristics
were compared with a group of previously described controls10 using the
Fisher exact test or Pearson chi-square test, whichever appropriate in case
Table 1. Patient characteristics
Clinical parameter Study population (n 49)
Sex: male/female 27/22
Age in years: median (range) 38 (16-56)
Diagnosis
AML CR1 11
AML CR1 2
ALL CR1 4
ALL CR1 2
CML CP1 7
CLL 2
Hodgkin 1
MDS 1
Multiple myeloma 9
NHL 9
SAA 1
Risk status: SR/PR 21/28
Donor type
Sib 35
MUD 14
Conditioning regimen
Cy/TBI 33
Cy/TBI/ATG 15
Bu/Cy 1
Graft characteristics
MNC 108/kg 0.09 (0.01-0.74)
CD34 106/kg 1.68 (0.53-11.1)
CD3 105/kg 2.0 (1.0-4.0)
CFU-GM 104/kg 19.0 (3.0-128.0)
Stem cell source
BM 37
PB 12
EBV serology (D/R)
D/R 44
D/R 1
D/R 1
D/R 3
AML CR1/ CR1 indicates acute myeloid leukemia first/subsequent complete
remission; ALL CR1/ CR1, acute lymphoblastic leukemia first/subsequent CR; CML
CP1, chronic myeloid leukemia in first chronic phase; CLL, chronic lymphocytic
leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; SAA,
severe aplastic anemia; SR/PR, standard-risk/poor-risk disease; Sib, genotypically
matched sibling donor; MUD, matched unrelated donor; Cy, cyclophosphamide; TBI,
total body irradiation; ATG, antithymocyte globulin; Bu, busulphan; MNC, mono-
nuclear cells; CFU-GM, granulocyte macrophage-colony-forming units; BM, bone
marrow; PB, peripheral blood; EBV, Epstein-Barr virus; D/, donor EBV-
seropositive/-negative; R/, recipient EBV-seropositive/-negative.
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of discrete variables, or the Wilcoxon rank-sum test in case of continuous
variables. Time to EBV reactivation more than or equal to 1000 geq/mL was
determined from the date of SCT until the date of last plasma sample. Time
to EBV-LPD was measured from the date of viral reactivation more than or
equal to 1000 geq/mL. Patients without EBV-LPD were censored at the date
of death or last follow-up. LPD mortality was calculated from SCT until
death due to progressive LPD. Time to viral reactivation, time to EBV-LPD,
and LPD mortality were estimated by the Kaplan-Meier method,21 and the
Kaplan-Meier curves of the 2 cohorts were compared using the logrank
test.22 All reported P values are 2-sided and a significance level of   .05
was used.
Results
EBV reactivation and preemptive therapy
There were 27 (55%) of 49 prospectively studied patients who
showed EBV reactivation and 17 (35%) who progressed to a viral
load of more than or equal to 1000 geq/mL. Median time to EBV
reactivation more than or equal to 1000 geq/mL was 112 days
(range, 39-189 days) after SCT. Median EBV-DNA level measured
2100 geq/mL (range, 500-14 000) prior to admission and a median
of 3 days (range, 1-14) elapsed between that day and initiation of
preemptive therapy. Of these 17 patients, 2 appeared to present
with active EBV-LPD upon examination (see below). The other 15
patients were eligible for preemptive therapy and received ritux-
imab at a median time of 113 days after SCT (range, 41-202 days).
Of 15 treated patients, 14 had a complete and sustained response.
EBV-DNA in plasma became undetectable after a median of 8 days
(range, 1-46 days) (Table 2). Recurrent reactivations were not
observed in any of these patients with a median follow up of 12
months (range, 1-24 months). One patient (case no. 5) did not
respond as was evident by a continuing increase of viral load and
progression to EBV-LPD. This patient was treated with a second
infusion of rituximab (375 mg/m2) and DLI (1 106 CD3 T
cells/kg) (Table 2), and had a sustained response without subse-
quent EBV reactivation.
B-cell numbers rapidly declined following rituximab infusion
and became undetectable in 12 out of 15 patients. B-cell lymphope-
nia in these patients persisted for several months (Figure 1) and
recovery started at approximately 6 months from preemptive
therapy. Opportunistic infections (common toxicity criteria [CTC]
grade 3 or 4) were observed in all 8 patients having extensive
chronic GVHD. In contrast, only 3 out of 7 patients without
extensive chronic GVHD experienced CTC grade 3 or 4 infections
following rituximab treatment (P  .03). There were 4 B-cell
lymphopenic patients who developed pneumonia, including 2
polymicrobial pneumonias (bacterial, 2; fungal, 4; viral, 1); all
these 4 patients suffered at the time from extensive chronic GVHD
necessitating intensive immunosuppressive therapy. Neutropenia
(absolute neutrophil count  0.5 109/L) within 4 weeks of
infusion occurred in only 2 of the 15 patients; both had chronic
extensive GVHD. The single patient (case no. 5, Table 2), who
failed preemptive therapy and was treated using DLI, developed
bronchiolitis obliterans organizing pneumonia, complicated by
bacterial pneumonia.
There were 2 patients who presented with lymphadenopathy at
the time of admission and who were not eligible for preemptive
therapy, because pathologic and immunologic examinations of
lymph node biopsies were consistent with a diagnosis of EBV-
LPD. Both patients had received a TCD unrelated donor graft and
Figure 1. B-cell lymphopenia following rituximab treatment. Median and indi-
vidual peripheral blood B-cell numbers in recipients of a TCD allo-SCT with EBV-DNA
more than or equal to 1000 geq/mL before and after preemptive rituximab (PE-
therapy) given at day 0 (dashed line denotes detection limit of assay; horizontal solid
lines indicate median value).
Table 2. Preemptive rituximab after T-cell-depleted allogeneic stem cell transplantation for prevention of Epstein-Barr virus-lymphoproliferative disease
Patient
no.
Donor
type
EBV 1 000 geq/mL Initiation of
preemptive rituximab
(d*)
Max EBV-DNA level
(geq/mL)
EBV 50
(geq/mL, d after start
preemptive rituximab) EBV-LPDDay of onset* EBV load
1 Sib 73 2 700 84 5 800 12 
2 Sib 122 2 300 129 2 300 6 
3 Sib 150 1 400 157 2 800 14 
4 Sib 188 2 100 202 3 800 5 
5 MUD 47 3 300 50 1 100 000 46 
6 MUD 39 8 800 43 675 000 45 
7 Sib 129 14 000 133 85 000 6 
8 Sib 108 1 400 110 1 400 7 
9 Sib 171 3 000 174 110 000 26 
10 MUD 118 1 800 125 1 800 27 
11 MUD 46 2 100 47 2 100 1 
12 Sib 61 3 600 63 3 600 4 
13 Sib 112 1 800 113 15 000 8 
14 MUD 40 500 41 1 350 21 
15 Sib 189 1 200 192 1 150 4 
*Days after stem cell transplantation.
Sib indicates HLA genotypically matched sibling donor; MUD, matched unrelated donor; EBV, Epstein-Barr virus; geq/mL, genome equivalents/milliliter; EBV-LPD,
EBV-lymphoproliferative disease.
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had also received ATG as part of the conditioning regimen. They
showed rapid progression of viral reactivation with 2 and 7 days,
respectively, between the first signs of reactivation and the onset of
lymphadenopathy (Figure 2). These 2 patients were enrolled in a
therapeutical protocol, including 2 infusions of rituximab guided
by viral load. Both patients obtained a complete response and they
are alive at the date of last follow-up, day 338 and day 415,
respectively. EBV-DNA levels were 8750 geq/mL and 17 500
geq/mL at the time of clinical admission and complete and
persistent clearance of EBV-DNA was achieved after 16 days and
34 days, respectively (Figure 2).
Comparison with historical cohort
The positive and negative predictive values of a viral load of 1000
geq/mL have been established in a group of 85 recipients of a TCD
allo-SCT.10 Plasma samples were retrospectively examined for
EBV reactivation at weekly intervals in these 85 patients. Consider-
ing a threshold level of 1000 geq/mL, the negative predictive value
was 100%. The cumulative probability of developing EBV-LPD
was 38% 11% at 2 months and 49% 11% at 4 months from the
date of EBV-DNA more than or equal to 1000 geq/mL (Figure 3A).
Results of the current prospective study were compared with those
historical controls with respect to EBV reactivation, incidence of
EBV-LPD, and LPD mortality. Patient characteristics of patients at
high risk of progression to EBV-LPD, as defined by reactivation of
more than or equal to 1000 geq/mL after a TCD allo-SCT, did not
differ between prospectively followed patients (n 17) and con-
trols (n 26, Table 3). In both cohorts, the majority of patients
suffered from poor-risk underlying disease. In the historical cohort,
42% of patients had received ATG and an unrelated donor graft, as
compared with 41% in the prospective cohort. In addition, graft
characteristics were similar (Table 3). GVHD prophylaxis was
similar in both cohorts and consisted of TCD and cyclosporin A
when a sibling donor was used; ATG was added in case of a MUD
SCT. Cumulative incidences (CI) of acute and chronic GVHD did
not differ between both cohorts. The CI of acute GVHD grade II
to IV was 51% at 100 days post-SCT versus 54% at 100 days
for prospectively followed patients and historical controls, respec-
tively. The CI for chronic GVHD (limited and extensive) was
37% for prospectively followed patients versus 36% in the
historical cohort.
The probabilities of viral reactivation more than 50 geq/mL and
more than or equal to 1000 geq/mL were similar in both cohorts.
Probabilities of EBV reactivation ( 1000 geq/mL) at 4 months from
SCT were 26% 5% versus 28% 7% for historical controls and
prospectively monitored patients, respectively (Figure 4).
Among the historical group, 10 of 26 patients developed
EBV-LPD, of whom 5 died due to progressive EBV-LPD despite
the therapeutic use of rituximab and DLI, and 3 other patients died
due to extensive chronic GVHD secondary to DLI. Among the
prospectively monitored patients, 1 of 15 patients treated preemp-
tively developed EBV-LPD and 2 other patients presented with
EBV-LPD before initiation of preemptive therapy (Figure 3A,
P  .13). None of these 17 patients died from progressive EBV-
LPD (Figure 3B, P  .04). Viral reactivation was abrogated in all
of these 17 patients without any recurrences.
Figure 2. Viral load following therapy for established EBV-LPD. EBV load in 2
recipients of a TCD allo-SCT with established EBV-LPD prior to planned preemptive
therapy. EBV-LPD was diagnosed on lymph node biopsies in both patients at the day
of first rituximab infusion. Both patients developed a sustained complete response
after 2 successive infusions of rituximab combined with dose reduction of cyclosporin
(2 denotes diagnosis of EBV-LPD; asterisk indicates single infusion of 375 mg/m2
rituximab).
Figure 3. Incidence of EBV-LPD and EBV-LPD mortality as compared to
historical controls. (A) Incidence of EBV-LPD. Cumulative incidence of EBV-LPD in
historical control patients (n  26) with EBV-DNA more than or equal to 1000 geq/mL
versus the incidence of EBV-LPD in the prospectively followed group after EBV-DNA
more than or equal to 1000 geq/mL (n  17) (P  .13). (B) EBV-LPD mortality.
Cumulative incidence of EBV-LPD mortality in historical control patients (n  26) with
EBV-DNA more than or equal to 1000 geq/mL versus the incidence of EBV-LPD
mortality in patients (n  17) prospectively studied (P  .04). N indicates numbers of
patients studied; O, observations (endpoints) done in the study group.
Table 3. Characteristics of high-risk patients
Parameter Historical cohort (n 26) Prospective study (n 17)
Age 40 (18-55) 40 (19-51)
Underlying disease
Risk status
SR/PR 2/24 4/13
Donor type
Sib 15 10
MUD 11 7
ATG 11 7
Stem cell source
Bone marrow 24 14
Peripheral blood 2 3
Graft characteristics
CD3 (105/kg) 2.0 (1.0-6.8) 2.0 (1.0-4.0)
CD34 (106/kg) 1.6 (0.26-4.57) 1.7 (0.53-8.10)
High-risk, as defined by (1) allogeneic stem cell transplantation by partial T-cell
depletion, and (2) Epstein-Barr virus load 1000 geq/mL.
SR/PR indicates standard-risk/poor-risk disease; Sib, HLA-genotypically matched
sibling donor; MUD, matched unrelated donor; ATG, antithymocyte globulin.
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Discussion
The present study shows that preemptive rituximab selectively
administered to high-risk patients abrogates EBV reactivation and
reduces the incidence of EBV-LPD. Furthermore, mortality due to
EBV-LPD no longer contributed to treatment-related mortality in
these prospectively monitored patients with EBV reactivation after
TCD allo-SCT.
Outcome of clinically established EBV-LPD is still not optimal,
although new promising treatment modalities have been intro-
duced, such as anti-CD20 immunotherapy12,14,17,18 and adoptive
T-cell immunotherapy.13,23-25 Failure of treatment may be due to
rapidly progressive EBV-LPD,9-11,14 development of resistance,26
viral immune evasion,27 and loss of CD20 antigen expression.28
Studies focusing on the therapeutic value of rituximab have shown
a mortality of 17% to 25% due to progressive LPD.14,17 In addition,
GVHD following donor lymphocyte infusion may also adversely
affect outcome.9,10,13,23 Therefore, effective preventive approaches
may be preferred to reduce mortality associated with EBV-LPD.
Such approaches, however, should specifically be developed for
high-risk patients, because EBV-LPD is a rare complication after
allo-SCT and unnecessary treatment of patients with a low
probability should be avoided. Retrospectively, we established a
viral reactivation of 1000 geq/mL as a threshold value with high
positive and negative predictive values in recipients of a TCD
allo-SCT.10 Using that threshold value, we were now able to
selectively administer preemptive therapy to 15 out of 49 patients.
EBV-LPD was effectively prevented by rituximab in those recipi-
ents. Only 1 out of 15 patients receiving preemptive therapy
progressed to EBV-LPD, but the patient was rescued by a second
infusion of rituximab and DLI as well. This patient had received
ATG prior to TCD allo-SCT, which may explain the more
aggressive evolution of viral reactivation toward EBV-LPD. Retro-
spectively, ATG was strongly associated with a higher incidence of
EBV reactivation and an earlier and more rapid evolution of
reactivation and a higher incidence of EBV-LPD.10,11,29 There were
2 other patients who had also received ATG and who showed early
viral reactivation, followed by rapid progression to EBV-LPD
before preemptive therapy could be instituted. However, both
patients developed a sustained complete response after a second
infusion of rituximab given at a relatively early time point in the
course of their disease, and EBV-LPD mortality was effectively
prevented. Although these patients escaped the preemptive ap-
proach, the frequent monitoring allowed an early diagnosis and
thereby an early therapeutic intervention.
Peripheral B-cell numbers rapidly declined following a single
infusion of rituximab and became undetectable in 12 patients. In
addition, B-cell lymphopenia persisted for several months (Figure
1). Only a few relatively mild infections were observed in B-cell
lymphopenic patients without chronic GVHD, which may be
explained by unaffected plasma cell counts and thereby unaffected
immunoglobulin production.15 In contrast, patients with B-cell
lymphopenia and chronic extensive GVHD appeared to be at
higher risk for opportunistic pneumonias, which may reflect the
immunodeficiency associated with chronic GVHD rather than with
B-cell lymphopenia as such. So far, patients treated with more
intensive rituximab immunotherapy in other studies have not
shown an increased risk of opportunistic infections despite effec-
tive and prolonged B-cell lymphopenia.15,16
The development of EBV-LPD is the result of uncontrolled
B-cell proliferation due to failure of immunologic control. There-
fore, other investigators have focused on a preemptive approach of
improving EBV-specific immunity in patients at high risk for
EBV-LPD and reported on preemptive infusion of EBV-specific
cytotoxic T cells (CTLs) in patients with elevated EBV-DNA
levels.24,25 Effective prevention of EBV-LPD was strongly sug-
gested by a decrease of viral DNA levels and a low incidence of
EBV-LPD in the patient populations studied. The approach is,
although attractive, hampered by the rather elaborate procedures
needed to prepare EBV-specific CTLs. These and other studies
have focused on detection of cellular EBV-DNA levels to identify
patients at highest risk of EBV-LPD.4-7,24,25 We have used a
quantitative PCR of EBV-DNA in plasma, which appeared to
accurately predict impending EBV-LPD as well as response to
therapy in recipients of a TCD allo-SCT.8-10 Especially in recipients
of stem cell transplants, quantification of viral load in plasma may
be advantageous, as the technique is relatively fast and simple and
patients with lymphopenia may have insufficient cell numbers for
reliable quantification of peripheral blood mononuclear cell viral
load. Furthermore, response to therapy of EBV-LPD may be
followed more accurately by plasma PCR, as suggested by our
findings and those of Van Esser et al9 and Yang et al.30 Our assay
may monitor lytic EBV infection and/or release of viral DNA from
latently infected B cells. If viral DNA is mainly derived from lytic
replication, our results may suggest that active lytic infection
contributes to the development of EBV-LPD, which would be in
line with a number of previous studies showing that active lytic
infection participates in the development of EBV-LPD.31-35 The
latter studies have raised the question whether the prophylactic or
preemptive administration of antiviral agents such as aciclovir or
ganciclovir would prevent EBV-LPD following transplantation of
allogeneic stem cells or allogeneic solid organs. However, preven-
tive approaches with these antiviral drugs have generally been
disappointing (reviewed by Davis31), which may be explained by
their inability to inhibit proliferating B cells, once these have
acquired an autonomous growth pattern.
In conclusion, we developed a risk-adapted strategy to abrogate
viral reactivation and prevent EBV-LPD. It is shown that a single
infusion of rituximab is effective as preemptive therapy for
EBV-LPD and prevention of EBV-LPD mortality in a selected
group of allo-SCT recipients at high-risk for EBV-LPD. Consider-
ing the possible rapid and aggressive evolution of viral reactivation
toward EBV-LPD in recipients having received ATG, the frequent
monitoring of reactivation and early institution of preemptive
therapy should be advocated in recipients treated with ATG.
Figure 4. Cumulative incidence of EBV reactivation more than or equal to 1000
geq/mL. Cumulative incidence of EBV reactivation more than or equal to 1000
geq/mL in prospectively studied EBV-seropositive donor/recipient pairs (n  48)
versus the incidence in the historical control group (n  85) (P  .86).
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